<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK390611" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK390611/" /><meta name="ncbi_pagename" content="BAP1 Tumor Predisposition Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>BAP1 Tumor Predisposition Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="BAP1 Tumor Predisposition Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/10/13" /><meta name="citation_author" content="Robert Pilarski" /><meta name="citation_author" content="Karan Rai" /><meta name="citation_author" content="Colleen Cebulla" /><meta name="citation_author" content="Mohamed Abdel-Rahman" /><meta name="citation_pmid" content="27748099" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK390611/" /><meta name="citation_keywords" content="BAP1 Cancer Syndrome" /><meta name="citation_keywords" content="BAP1-TPDS" /><meta name="citation_keywords" content="Cutaneous/Ocular Melanoma, Atypical Melanocytic Proliferations, and Other Internal Neoplasms (COMMON Syndrome)" /><meta name="citation_keywords" content="BAP1 Cancer Syndrome" /><meta name="citation_keywords" content="Cutaneous/Ocular Melanoma, Atypical Melanocytic Proliferations, and Other Internal Neoplasms (COMMON Syndrome)" /><meta name="citation_keywords" content="BAP1-TPDS" /><meta name="citation_keywords" content="Ubiquitin carboxyl-terminal hydrolase BAP1" /><meta name="citation_keywords" content="BAP1" /><meta name="citation_keywords" content="BAP1 Tumor Predisposition Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="BAP1 Tumor Predisposition Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Robert Pilarski" /><meta name="DC.Contributor" content="Karan Rai" /><meta name="DC.Contributor" content="Colleen Cebulla" /><meta name="DC.Contributor" content="Mohamed Abdel-Rahman" /><meta name="DC.Date" content="2016/10/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK390611/" /><meta name="description" content="BAP1 tumor predisposition syndrome (BAP1-TPDS) is associated with an increased risk for the specific skin lesion – atypical Spitz tumors – and the following cancers, in descending order of frequency: uveal (eye) melanoma (UM), malignant mesothelioma (MMe), cutaneous melanoma (CM), clear cell renal cell carcinoma (ccRCC), and basal cell carcinoma (BCC). Affected individuals can have more than one type of primary cancer. In general the median age of onset of these tumors is younger than in the general population. UM tends to be a more aggressive class 2 tumor with higher risk for metastasis and reduced survival compared to UM that occurs in the general population. However, because of the limited number of families reported to date, the penetrance, natural history, and frequencies of the BAP1-associated tumors are yet to be determined." /><meta name="og:title" content="BAP1 Tumor Predisposition Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="BAP1 tumor predisposition syndrome (BAP1-TPDS) is associated with an increased risk for the specific skin lesion – atypical Spitz tumors – and the following cancers, in descending order of frequency: uveal (eye) melanoma (UM), malignant mesothelioma (MMe), cutaneous melanoma (CM), clear cell renal cell carcinoma (ccRCC), and basal cell carcinoma (BCC). Affected individuals can have more than one type of primary cancer. In general the median age of onset of these tumors is younger than in the general population. UM tends to be a more aggressive class 2 tumor with higher risk for metastasis and reduced survival compared to UM that occurs in the general population. However, because of the limited number of families reported to date, the penetrance, natural history, and frequencies of the BAP1-associated tumors are yet to be determined." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK390611/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/bap1-tpds/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK390611/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BE21AE04180B10000000007DA02F9.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK390611_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK390611_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/li-ar/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bcl11a-id/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK390611_"><span class="title" itemprop="name"><i>BAP1</i> Tumor Predisposition Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: <i>BAP1</i> Cancer Syndrome; <i>BAP1</i>-TPDS; Cutaneous/Ocular Melanoma, Atypical Melanocytic Proliferations, and Other Internal Neoplasms (COMMON Syndrome)</div><p class="contrib-group"><span itemprop="author">Robert Pilarski</span>, MS,LGC, MSW, <span itemprop="author">Karan Rai</span>, BS, <span itemprop="author">Colleen Cebulla</span>, MD, PhD, and <span itemprop="author">Mohamed Abdel-Rahman</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK390611_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK390611_ai__"><div class="contrib half_rhythm"><span itemprop="author">Robert Pilarski</span>, MS,LGC, MSW<div class="affiliation small">Department of Internal Medicine and Comprehensive Cancer Center<br />The Ohio State University<br />Columbus, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuso@iksralip.trebor" class="oemail">ude.cmuso@iksralip.trebor</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Karan Rai</span>, BS<div class="affiliation small">Department of Internal Medicine and Comprehensive Cancer Center<br />The Ohio State University<br />Columbus, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuso@iar.narak" class="oemail">ude.cmuso@iar.narak</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Colleen Cebulla</span>, MD, PhD<div class="affiliation small">Department of Ophthalmology<br />The Ohio State University<br />Columbus, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuso@allubec.neelloc" class="oemail">ude.cmuso@allubec.neelloc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mohamed Abdel-Rahman</span>, MD, PhD<div class="affiliation small">Department of Ophthalmology<br />The Ohio State University<br />Columbus, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuso@namhar-ledba.demahom" class="oemail">ude.cmuso@namhar-ledba.demahom</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 13, 2016</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="bap1-tpds.Summary" itemprop="description"><h2 id="_bap1-tpds_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>BAP1</i> tumor predisposition syndrome (<i>BAP1</i>-TPDS) is associated with an increased risk for the specific skin lesion &#x02013; atypical Spitz tumors &#x02013; and the following cancers, in descending order of frequency: uveal (eye) melanoma (UM), malignant mesothelioma (MMe), cutaneous melanoma (CM), clear cell renal cell carcinoma (ccRCC), and basal cell carcinoma (BCC). Affected individuals can have more than one type of primary cancer. In general the median age of onset of these tumors is younger than in the general population. UM tends to be a more aggressive class 2 tumor with higher risk for metastasis and reduced survival compared to UM that occurs in the general population. However, because of the limited number of families reported to date, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, natural history, and frequencies of the <i>BAP1</i>-associated tumors are yet to be determined.</p><p>Other suspected but unconfirmed tumors in <i>BAP1</i>-TPDS include (in alphabetic order): breast cancer, cholangiocarcinoma, non-small cell lung adenocarcinoma (NSCLC), meningioma, and neuroendocrine carcinoma.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>BAP1</i>-TPDS is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BAP1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> The treatments for <i>BAP1</i>-TPDS tumors are those used in standard practice. UM: Because of the increased aggressiveness of <i>BAP1</i>-related uveal melanoma, all uveal melanomas should be managed as the more aggressive class 2 or <a class="def" href="/books/n/gene/glossary/def-item/monosomy/">monosomy</a> 3 tumors. MMe is highly refractory to conventional therapies including aggressive surgical intervention and multimodality strategies; thus, a cure is unlikely.</p><p><i>Prevention of primary manifestations:</i> UM: avoid arc-welding. No data exist regarding benefit of sunglasses for reduction of UM risk. MMe: avoid asbestos exposure and smoking. CM and BCC: limit sun exposure, use sunscreen and protective clothing, and have regular dermatologic examinations.</p><p><i>Surveillance:</i> UM: yearly dilated eye examinations and imaging by an ocular oncologist beginning around age 11 years. MMe: No screening modalities exist; however, annual physical examination is recommended. If an abdominal MRI is to be performed as recommended for ccRCC, consider evaluation of the peritoneum and pleura as well. Although some physicians recommend spiral chest CT for asymptomatic persons with a history of exposure to asbestos, others do not, given the possible increased risk of cancer from radiation exposure. CM, basal cell carcinoma, ASTs: Annual full-body dermatologic examinations beginning around age 20 years. ccRCC: annual abdominal ultrasound examination; consider annual urinalysis and abdominal MRI every two years.</p><p><i>Agents/circumstances to avoid:</i> see <i>Prevention of primary manifestations</i>.</p><p><i>Evaluation of relatives at risk:</i> Clarify the genetic status of apparently asymptomatic older and younger at-risk relatives by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family in order to identify as early as possible those who would benefit from prompt initiation of screening and preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>BAP1</i>-TPDS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. To date, most individuals diagnosed with <i>BAP1</i>-TPDS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent; the proportion of <i>BAP1</i>-TPDS caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown. Each child of an individual with <i>BAP1</i>-TPDS has a 50% chance of inheriting the <i>BAP1</i> pathogenic variant; however, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> appears to be incomplete and the types of <i>BAP1</i>-related tumors can vary among different members of the same family. Once the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk for <i>BAP1</i>-TPDS and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="bap1-tpds.Diagnosis"><h2 id="_bap1-tpds_Diagnosis_">Diagnosis</h2><p>No diagnostic criteria have been published for the <i>BAP1</i> tumor predisposition syndrome (<i>BAP1</i>-TPDS).</p><div id="bap1-tpds.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>BAP1</i> tumor predisposition syndrome (<i>BAP1</i>-TPDS) <b>should be suspected</b> in an individual who has EITHER of the following:</p><ul><li class="half_rhythm"><div>Two or more confirmed <i>BAP1</i>-TPDS tumors*</div><div>OR</div></li><li class="half_rhythm"><div>One <i>BAP1</i>-TPDS tumor and a first- or <a class="def" href="/books/n/gene/glossary/def-item/second-degree-relative/">second-degree relative</a> with a confirmed <i>BAP1</i>-TPDS tumor*</div></li></ul><p>* Excluding two basal cell cancers and/or cutaneous melanomas, given their high frequency in the general population</p><p>Confirmed <i>BAP1</i>-TPDS tumors include the following (in descending order of likelihood):</p><ul><li class="half_rhythm"><div>Atypical Spitz tumors (ASTs), which may be the most common manifestation of <i>BAP1</i>-TPDS, and may result in the initial identification of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. ASTs are skin-colored to reddish-brown, averaging 5 mm in diameter; the histologic findings are between those of a Spitz nevus and a melanoma. Both copies of <i>BAP1</i> are inactivated leading to loss of staining for the BAP1 protein on immunohistochemistry.</div></li><li class="half_rhythm"><div>Uveal (eye) melanoma</div></li><li class="half_rhythm"><div>Malignant mesothelioma (MMe)</div></li><li class="half_rhythm"><div>Cutaneous melanoma</div></li><li class="half_rhythm"><div>Clear cell renal cell carcinoma (ccRCC)</div></li><li class="half_rhythm"><div>Basal cell carcinoma</div></li></ul><p>Unconfirmed tumors (with conflicting evidence regarding inclusion in the <i>BAP1</i>-TPDS tumor spectrum) include the following (in alphabetic order):</p><ul><li class="half_rhythm"><div>Breast cancer</div></li><li class="half_rhythm"><div>Cholangiocarcinoma</div></li><li class="half_rhythm"><div>Meningioma</div></li><li class="half_rhythm"><div>Neuroendocrine tumors</div></li><li class="half_rhythm"><div>Non-small cell lung adenocarcinoma (NSCLC)</div></li><li class="half_rhythm"><div>Thyroid cancer</div></li></ul></div><div id="bap1-tpds.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>BAP1</i>-TPDS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BAP1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK390611/table/bap1-tpds.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figbap1tpdsTmoleculargenetictestingus" rid-ob="figobbap1tpdsTmoleculargenetictestingus">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>BAP1</i> is performed. To date, no published data exist regarding the benefit (or lack thereof) of doing gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found on <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>BAP1</i> and other genes of interest (see <a href="#bap1-tpds.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="bap1-tpds.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>BAP1</i> Tumor Predisposition Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK390611/table/bap1-tpds.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bap1-tpds.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>BAP1</i></td><td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All variants reported to date&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_bap1-tpds.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="bap1-tpds.TF.1.1"><p class="no_margin">See <a href="/books/NBK390611/#bap1-tpds.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="bap1-tpds.TF.1.2"><p class="no_margin">See <a href="#bap1-tpds.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="bap1-tpds.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="bap1-tpds.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al [2016]</a></p></div></dd><dt>5. </dt><dd><div id="bap1-tpds.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="bap1-tpds.TF.1.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available. Using MLPA, no <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or multiexon deletions/duplications were identified in 20 individuals with uveal melanoma and a family history of uveal melanoma or in ten individuals with uveal melanoma and a personal or family history of renal cell carcinoma [M Abdel-Rahman, unpublished data].</p></div></dd></dl></div></div></div></div></div><div id="bap1-tpds.Clinical_Characteristics"><h2 id="_bap1-tpds_Clinical_Characteristics_">Clinical Characteristics</h2><div id="bap1-tpds.Clinical_Description"><h3>Clinical Description</h3><p><i>BAP1</i> tumor predisposition syndrome (<i>BAP1</i>-TPDS) is associated with an increased risk for a number of cancers and a specific skin lesion (atypical Spitz tumors). Affected individuals can have more than one type of primary cancer [<a class="bk_pop" href="#bap1-tpds.REF.testa.2011.1022">Testa et al 2011</a>, <a class="bk_pop" href="#bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</a>, <a class="bk_pop" href="#bap1-tpds.REF.aoude.2013b.e72144">Aoude et al 2013b</a>, <a class="bk_pop" href="#bap1-tpds.REF.cheung.2015.261">Cheung et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</a>, <a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>].</p><p>Because of the limited number of families reported to date and because of the ascertainment bias of the interests of the research groups focusing on uveal melanoma, malignant mesothelioma, and cutaneous melanoma, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> and frequencies of the various <i>BAP1</i>-associated tumors are yet to be determined. It has been well established, however, that the following tumor types are associated with <i>BAP1</i>-TPDS.</p><p><b>Atypical Spitz tumors</b>
<b>(ASTs).</b>
<a class="bk_pop" href="#bap1-tpds.REF.wiesner.2012.818">Wiesner et al [2012]</a> categorized these skin lesions as &#x0201c;atypical Spitz tumors&#x0201d;; the authors agree that this is the most appropriate designation (see <a href="#bap1-tpds.Nomenclature">Nomenclature</a> for other terms used to describe these tumors).</p><p><b>Uveal melanoma (UM)</b> is the cancer most commonly reported in persons with <i>BAP1</i>-TPDS; 31% of those reported with <i>BAP1</i>-TPDS have UM. UM is the cancer with the earliest reported age of diagnosis (age 16 years) [<a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>].</p><p>Median age of onset of UM in persons with <i>BAP1</i>-TPDS is 51 years, which is younger than the onset of UM in the general population (62 years). The tumors are generally more aggressive class 2 (i.e., high metastatic risk) tumors with higher risk for metastasis and reduced survival [<a class="bk_pop" href="#bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</a>, <a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>]. In one study, mean length of survival in persons whose uveal melanoma tumor lacked BAP1 expression was 4.74 years compared to 9.97 years in persons whose tumors expressed BAP1 [<a class="bk_pop" href="#bap1-tpds.REF.kalirai.2014.1373">Kalirai et al 2014</a>].</p><p><b>Malignant mesothelioma (MMe)</b> is the second most frequent cancer (22%) identified in <i>BAP1</i>-TPDS [<a class="bk_pop" href="#bap1-tpds.REF.testa.2011.1022">Testa et al 2011</a>, <a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>].</p><p>Two studies [<a class="bk_pop" href="#bap1-tpds.REF.baumann.2015.76">Baumann et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</a>] have shown that the median age of onset of MMe in individuals with <i>BAP1</i>-TPDS was significantly earlier (55 and 58 years, respectively) than that of <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> MMe (72 and 68 years, respectively).</p><p>Generally, pleural MMe accounts for about 80% and peritoneal MMe constitutes most of the remaining MMe. However, in individuals with <i>BAP1</i>-TPDS the ratio of peritoneal to pleural involvement is significantly higher [<a class="bk_pop" href="#bap1-tpds.REF.carbone.2015.e1005633">Carbone et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.cheung.2015.261">Cheung et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</a>]. In <i>BAP1</i>-TPDS the majority of peritoneal MMe occurs in women, in contrast to the general population, in which men are more likely to have this tumor type [<a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>].</p><p>In contrast to survival in persons with <i>BAP1</i>-related cutaneous melanoma, uveal melanoma, or renal cell carcinoma, survival in persons with <i>BAP1</i>-related MMe may be significantly longer [<a class="bk_pop" href="#bap1-tpds.REF.de_reyni_s.2014.1323">de Reyni&#x000e8;s et al 2014</a>, <a class="bk_pop" href="#bap1-tpds.REF.baumann.2015.76">Baumann et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.carbone.2015.e1005633">Carbone et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</a>]; however, to date the data are not consistent [<a class="bk_pop" href="#bap1-tpds.REF.singhi.2016.14">Singhi et al 2016</a>].</p><p>Growing evidence suggests that <i>BAP1</i> pathogenic variants interact with environmental asbestos exposure to increase the risk for MMe [<a class="bk_pop" href="#bap1-tpds.REF.xu.2014.4388">Xu et al 2014</a>, <a class="bk_pop" href="#bap1-tpds.REF.kadariya.2016.2836">Kadariya et al 2016</a>].</p><p><b>Cutaneous melanoma (CM).</b> First reported in association with <i>BAP1</i>-TPDS in 2011, CM is now known to be the third most common cancer in <i>BAP1</i>-TPDS, occurring in 13% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#bap1-tpds.REF.wiesner.2011.1018">Wiesner et al 2011</a>]. Multiple primary cutaneous melanomas are common. The median age of onset of CM in <i>BAP1</i>-TPDS is earlier than in the general population (46 vs 58 years). Although it is possible that <i>BAP1-</i>related CM is more aggressive than cutaneous melanoma in the general population, to date the data are inconsistent [<a class="bk_pop" href="#bap1-tpds.REF.gupta.2015.881">Gupta et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.kumar.2015.1089">Kumar et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>].</p><p><b>Clear cell renal cell carcinoma (ccRCC).</b> Heterozygous <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants are specifically associated with an increased risk for ccRCC [<a class="bk_pop" href="#bap1-tpds.REF.haas.2014.81">Haas &#x00026; Nathanson 2014</a>]. Median age of ccRCC diagnosis appears to be younger in persons with <i>BAP1</i>-TPDS than in the general population (47 vs 64 years), and length of survival is decreased in persons with <i>BAP1-</i>related ccRCC [<a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>]. Histology of these tumors is distinct from tumors not associated with pathogenic variants in <i>BAP1</i>, with higher grade at diagnosis and lack of <i>PBRM1</i> pathogenic variants (which are common in ccRCC not associated with pathogenic variants in <i>BAP1</i>) [<a class="bk_pop" href="#bap1-tpds.REF.pe_allopis.2012.751">Pe&#x000f1;a-Llopis et al 2012</a>].</p><p><b>Basal cell carcinoma</b> has recently been confirmed as a tumor in the <i>BAP1</i>-TPDS spectrum [<a class="bk_pop" href="#bap1-tpds.REF.de_la_fouchardi_re.2015a.273">de la Fouchardi&#x000e8;re et al 2015a</a>, <a class="bk_pop" href="#bap1-tpds.REF.mochel.2015.901">Mochel et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.wadt.2015.267">Wadt et al 2015</a>]. Multiple primary basal cell carcinomas are common. Based on limited information, the median age of diagnosis appears to be around 50 years.</p><p><b>Other cancers</b> with some evidence (although inconsistent) supporting inclusion in the <i>BAP1</i>-TPDS spectrum are the following (in alphabetic order):</p><ul><li class="half_rhythm"><div>Breast cancer [<a class="bk_pop" href="#bap1-tpds.REF.testa.2011.1022">Testa et al 2011</a>, <a class="bk_pop" href="#bap1-tpds.REF.njauw.2012.e35295">Njauw at al 2012</a>, <a class="bk_pop" href="#bap1-tpds.REF.popova.2013.974">Popova et al 2013</a>, <a class="bk_pop" href="#bap1-tpds.REF.pilarski.2014.177">Pilarski et al 2014</a>]</div></li><li class="half_rhythm"><div>Cholangiocarcinoma [<a class="bk_pop" href="#bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</a>, <a class="bk_pop" href="#bap1-tpds.REF.pilarski.2014.177">Pilarski et al 2014</a>, <a class="bk_pop" href="#bap1-tpds.REF.wadt.2015.267">Wadt et al 2015</a>]</div></li><li class="half_rhythm"><div>Meningioma [<a class="bk_pop" href="#bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</a>, <a class="bk_pop" href="#bap1-tpds.REF.cheung.2015.261">Cheung et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.de_la_fouchardi_re.2015b.921">de la Fouchardi&#x000e8;re et al 2015b</a>, <a class="bk_pop" href="#bap1-tpds.REF.wadt.2015.267">Wadt et al 2015</a>]</div></li><li class="half_rhythm"><div>Neuroendocrine tumors [<a class="bk_pop" href="#bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</a>, <a class="bk_pop" href="#bap1-tpds.REF.wadt.2012.815">Wadt et al 2012</a>]</div></li><li class="half_rhythm"><div>Non-small cell lung adenocarcinoma (NSCLC) [<a class="bk_pop" href="#bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</a>, <a class="bk_pop" href="#bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</a>, <a class="bk_pop" href="#bap1-tpds.REF.wadt.2012.815">Wadt et al 2012</a>, <a class="bk_pop" href="#bap1-tpds.REF.aoude.2013b.e72144">Aoude et al 2013b</a>]</div></li><li class="half_rhythm"><div>Thyroid cancer [<a class="bk_pop" href="#bap1-tpds.REF.popova.2013.974">Popova et al 2013</a>, <a class="bk_pop" href="#bap1-tpds.REF.mcdonnell.2016.75">McDonnell et al 2016</a>]</div></li></ul></div><div id="bap1-tpds.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>To date no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are published for <i>BAP1-</i>TPDS.</p><p>Most families (46 of 57) have had a unique <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; only five recurrent pathogenic variants have been reported [<a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>] (see <a href="#bap1-tpds.Molecular_Genetics">Molecular Genetics</a>).</p></div><div id="bap1-tpds.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the <i>BAP1</i>-TPDS appears to be high based on the published literature. In their review <a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al [2016]</a> found that 148/174 (85%) individuals reported with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> had a cancer diagnosis. However, ascertainment biases in favor of both testing and reporting <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> versus unaffected individuals may have inflated this figure. For example, in more than half of the reported families only the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> had been tested. Given these biases, an accurate estimate of penetrance cannot be determined at this time.</p></div><div id="bap1-tpds.Nomenclature"><h3>Nomenclature</h3><p>Atypical Spitz tumors have also been called the following:</p><ul><li class="half_rhythm"><div>Nevoid melanoma-like melanocytic proliferations (NEMMP) [<a class="bk_pop" href="#bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</a>]</div></li><li class="half_rhythm"><div>Melanocytic <i>BAP1</i>-mutated atypical intradermal tumors (MBAITS) [<a class="bk_pop" href="#bap1-tpds.REF.carbone.2012.179">Carbone et al 2012</a>]</div></li><li class="half_rhythm"><div>BAPoma [Author, personal observation]</div></li></ul></div><div id="bap1-tpds.Prevalence"><h3>Prevalence</h3><p>The prevalence of <i>BAP1</i>-TPDS is unknown. A 2015 review identified 57 published families with 174 individuals with <i>BAP1</i>-TPDS [<a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>].</p><p>The data on the prevalence of <i>BAP1</i>-TPDS in persons with uveal melanoma, mesothelioma, cutaneous melanoma, and <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> renal cell carcinoma are limited. The prevalence of <i>BAP1</i>-TPDS in persons with other cancers is unknown.</p><p>Of note, in one review 90% of families reported with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> met the criteria outlined in <a href="#bap1-tpds.Suggestive_Findings">Suggestive Findings</a> [<a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>]; whereas germline <i>BAP1</i> pathogenic variants are rare in unselected series of individuals with one tumor type or families with multiple members with only one tumor type (i.e., uveal melanoma [<a class="bk_pop" href="#bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman et al 2011</a>, <a class="bk_pop" href="#bap1-tpds.REF.turunen.2016.1112">Turunen et al 2016</a>], mesothelioma [<a class="bk_pop" href="#bap1-tpds.REF.testa.2011.1022">Testa et al 2011</a>], cutaneous melanoma [<a class="bk_pop" href="#bap1-tpds.REF.aoude.2015.126">Aoude et al 2015</a>], or renal cell carcinoma [<a class="bk_pop" href="#bap1-tpds.REF.farley.2013.1061">Farley et al 2013</a>, <a class="bk_pop" href="#bap1-tpds.REF.popova.2013.974">Popova et al 2013</a>]).</p><p><b>Uveal melanoma.</b> The prevalence of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> pathogenic variants in unselected individuals with uveal melanoma is 1%-2% [<a class="bk_pop" href="#bap1-tpds.REF.aoude.2013a.278">Aoude et al 2013a</a>]; in contrast, the frequency is 20%-30% in persons with uveal melanoma who have a family history of uveal melanoma [<a class="bk_pop" href="#bap1-tpds.REF.popova.2013.974">Popova et al 2013</a>, <a class="bk_pop" href="#bap1-tpds.REF.gupta.2015.881">Gupta et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.turunen.2016.1112">Turunen et al 2016</a>].</p><p><b>Malignant mesothelioma (MMe).</b> Germline <i>BAP1</i> pathogenic variants have been identified in 6% (9/153) to 20% (1/5) of individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> mesothelioma [<a class="bk_pop" href="#bap1-tpds.REF.betti.2015.51">Betti et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</a>]; however they are rare in <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence of MMe in a family) [<a class="bk_pop" href="#bap1-tpds.REF.rusch.2014.271">Rusch et al 2014</a>, <a class="bk_pop" href="#bap1-tpds.REF.betti.2015.51">Betti et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.sneddon.2015.103">Sneddon et al 2015</a>, <a class="bk_pop" href="#bap1-tpds.REF.ohar.2016.206">Ohar et al 2016</a>].</p><p><b>Cutaneous melanoma.</b> A <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant was identified in 0.63% of a population-based cohort of 1109 probands with cutaneous melanoma [<a class="bk_pop" href="#bap1-tpds.REF.aoude.2015.126">Aoude et al 2015</a>].</p></div></div><div id="bap1-tpds.Genetically_Related_Allelic_Di"><h2 id="_bap1-tpds_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>BAP1</i>.</p><p>Somatic <i>BAP1</i> variants have been found in some of the tumor types that are components of <i>BAP1</i>-TPDS as well as in other tumor types. These variants are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> and not heritable. For more details see Molecular Genetics, <a href="#bap1-tpds.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p></div><div id="bap1-tpds.Differential_Diagnosis"><h2 id="_bap1-tpds_Differential_Diagnosis_">Differential Diagnosis</h2><p>Mutation of other genes can be associated with uveal melanoma, malignant mesothelioma, renal cell carcinoma, and atypical Spitz tumors; however, no other <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is known to be associated with increased risk for the <b>combination of these cancers</b>, as is seen in <i>BAP1</i> tumor predisposition syndrome (<i>BAP1</i>-TPDS).</p><div id="bap1-tpds.T.disorders_and_genes_to_consi" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders and Genes to Consider in the Differential Diagnosis <i>BAP1</i>-TPDS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK390611/table/bap1-tpds.T.disorders_and_genes_to_consi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bap1-tpds.T.disorders_and_genes_to_consi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Cancer Type/Associated Disorder</th><th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comments and References</th></tr></thead><tbody><tr><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Uveal melanoma</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRCA2</i></td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#bap1-tpds.REF.iscovich.2002.42">Iscovich et al [2002]</a>, <a class="bk_pop" href="#bap1-tpds.REF.scott.2002.188">Scott et al [2002]</a>, <a class="bk_pop" href="#bap1-tpds.REF.sinilnikova.1999.325">Sinilnikova et al [1999]</a></td></tr><tr><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Malignant mesothelioma</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cutaneous melanoma</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CDKN2A</i><br /><i>CDK4</i><br /><i>MC1R</i><br /><i>MITF</i></td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pancreatic cancer is associated w/mutation of <i>CDKN2A</i> [<a class="bk_pop" href="#bap1-tpds.REF.marzukaalcal_.2014.381">Marzuka-Alcal&#x000e1; et al 2014</a>].</td></tr><tr><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Familial<br />clear cell<br />renal cell<br />carcinoma</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/paragangliomas/">Hereditary paraganglioma-pheochromocytoma syndromes</a></td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SDHA</i><br /><i>SDHB</i><br /><i>SDHC</i><br /><i>SDHD</i><br /><i>SDHAF2</i><br /><i>MAX</i></td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/vhl/">Von Hippel-Lindau syndrome</a></td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VHL</i></td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Translocation <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 3</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_bap1-tpds.T.disorders_and_genes_to_consi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OMIM <a href="http://omim.org/entry/144700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">144700</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd></dl></div></div></div></div><div id="bap1-tpds.Management"><h2 id="_bap1-tpds_Management_">Management</h2><div id="bap1-tpds.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>BAP1</i> tumor predisposition syndrome (<i>BAP1</i>-TPDS), the following evaluations are recommended [<a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>]:</p><ul><li class="half_rhythm"><div><b>Atypical Spitz (ATS) tumors, cutaneous melanoma (CM), and/or basal cell carcinoma (BCC).</b> Full-body skin examination by a dermatologist with excision of any lesions suggestive of an atypical Spitz tumor</div></li><li class="half_rhythm"><div><b>Uveal melanoma (UM).</b> Dilated eye examination and imaging by an ocular oncologist</div></li><li class="half_rhythm"><div><b>Malignant mesothelioma (MMe).</b> No screening modalities exist; however, if an abdominal MRI is to be performed as recommended for ccRCC, consider evaluation of the peritoneum and pleura as well. Although some physicians recommend spiral chest CT for asymptomatic persons with a history of exposure to asbestos, others do not, given the possible increased risk of cancer from radiation exposure.</div></li><li class="half_rhythm"><div><b>Clear cell renal cell carcinoma (ccRCC).</b> Abdominal ultrasound examination, urinalysis, and abdominal MRI (consider also requesting assessment of the pleura and peritoneum)</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="bap1-tpds.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The treatments for <i>BAP1</i>-TPDS tumors are those used in standard practice.</p><ul><li class="half_rhythm"><div><b>Uveal melanoma</b>. Because of the increased aggressiveness of <i>BAP1</i>-related uveal melanoma, all uveal melanomas should be managed as the more aggressive tumors (ie., those determined to be class 2 by expression profiling and those with <a class="def" href="/books/n/gene/glossary/def-item/monosomy/">monosomy</a> 3) [<a class="bk_pop" href="#bap1-tpds.REF.njauw.2012.e35295">Njauw et al 2012</a>].</div></li><li class="half_rhythm"><div><b>Malignant mesothelioma</b>. MMe is highly refractory to conventional therapies including aggressive surgical intervention and multimodality strategies; thus, a cure is unlikely.</div></li><li class="half_rhythm"><div><b>Clear cell renal cell carcinoma</b> is treated in the usual manner.</div></li></ul></div><div id="bap1-tpds.Prevention_of_Primary_Manifest"><h3>Prevention of Primary Manifestations</h3><p><b>Uveal melanoma.</b> Arc welding has been associated with risk of uveal melanoma and this should be avoided if possible.</p><p>Sunglasses with high UVA and UVB protection can reduce risk of cancer on the eyelids, but data regarding the benefit of sunglasses for uveal melanoma are lacking.</p><p><b>Malignant mesothelioma.</b> As with all individuals, asbestos exposure and smoking should also be avoided.</p><p><b>Cutaneous melanoma.</b> Primary prevention is limited to those measures typically used to reduce the risk for cutaneous melanoma, including limiting of sun exposure, regular use of sunscreen and protective clothing, and regular dermatologic examinations.</p></div><div id="bap1-tpds.Surveillance"><h3>Surveillance</h3><p>Consensus management recommendations have not been established; however, several groups have proposed variations of the following [<a class="bk_pop" href="#bap1-tpds.REF.carbone.2012.179">Carbone et al 2012</a>, <a class="bk_pop" href="#bap1-tpds.REF.battaglia.2014.37">Battaglia 2014</a>, <a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Uveal melanoma.</b> Yearly dilated eye examinations and imaging by an ocular oncologist beginning around age 11 years</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Malignant mesothelioma.</b> No reliable early disease symptoms or screening modalities</div><div class="half_rhythm">Annual evaluation is recommended for late manifestations of mesothelioma, which can include chest pain, cough, fever, shortness of breath, dysphagia, hoarseness, weight loss, fever, upper body and face edema (chest mesothelioma) and abdominal pain, ascites, nausea, vomiting, and/or constipation (peritoneal mesothelioma). Annual physical examination is recommended to look for signs of pleurisy (pleural inflammation), peritonitis, ascites and/or pleural effusion.</div><div class="half_rhythm">If an abdominal MRI is to be performed as recommended for ccRCC, consider evaluation of the peritoneum and pleura as well. Although some physicians recommend spiral chest CT for asymptomatic persons with a history of exposure to asbestos, others do not, given the possible increased risk of cancer from radiation exposure.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Cutaneous melanoma, basal cell carcinoma and atypical Spitz tumors.</b> Annual full body dermatologic examinations beginning around age 20 years</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Clear cell renal cell carcinoma.</b> Protocol similar to <a href="/books/n/gene/vhl/">von Hippel Lindau disease</a> with annual abdominal ultrasound examination; consideration of annual urinalysis and abdominal MRI every two years</div></li></ul></div><div id="bap1-tpds.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Arc welding</div></li><li class="half_rhythm"><div>Asbestos</div></li><li class="half_rhythm"><div>Smoking</div></li><li class="half_rhythm"><div>Unnecessary and prolonged sun exposure</div></li></ul></div><div id="bap1-tpds.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family in order to identify as early as possible those who would benefit from prompt initiation of screening and preventive measures.</p><p>See <a href="#bap1-tpds.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="bap1-tpds.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Currently no open treatment trials specifically target patients with <i>BAP1</i>-TPDS.</p><p>One NCI-sponsored <a href="https://clinicaltrials.gov/ct2/show/NCT01587352?term=bap1&#x00026;rank=3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">trial</a> using vorinostat in the treatment of metastatic uveal melanoma is assessing <i>BAP1</i> mutation status as a secondary outcome measure.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="bap1-tpds.Genetic_Counseling"><h2 id="_bap1-tpds_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="bap1-tpds.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>BAP1</i> tumor predisposition syndrome <i>(BAP1</i>-TPDS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="bap1-tpds.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>To date, most individuals diagnosed with <i>BAP1</i>-TPDS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. An affected parent may have <i>BAP1</i>-related tumors that differ from those of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div>Some individuals diagnosed with <i>BAP1</i>-TPDS may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of <i>BAP1</i>-TPDS caused by a <i>de novo</i> pathogenic variant is unknown.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent (although no instances of germline mosaicism have been reported to date, it remains a possibility).</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with <i>BAP1</i>-TPDS may appear to be negative because of failure to recognize the disorder in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has confirmed that neither of the parents has the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> (including the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>) for the variant and may never have developed a <i>BAP1</i>-related tumor; however, this has not been reported to date for <i>BAP1</i>-TPDS.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband&#x02019;s parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%. However, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> appears to be incomplete (see <a href="#bap1-tpds.Penetrance">Penetrance</a>) and the types of <i>BAP1</i>-related tumors can vary among different members of the same family.</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk for <i>BAP1</i>-TPDS because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li><li class="half_rhythm"><div>If the <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population (though still &#x0003c;1%) because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <i>BAP1</i>-TPDS has a 50% chance of inheriting the <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. However, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> appears to be incomplete and the types of <i>BAP1</i>-related tumors can vary among different members of the same family.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="bap1-tpds.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#bap1-tpds.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Predictive testing</b> for at-risk asymptomatic adult family members requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Genetic cancer risk assessment and counseling.</b> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, see <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</a> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="bap1-tpds.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for <i>BAP1</i>-TPDS are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="bap1-tpds.Resources"><h2 id="_bap1-tpds_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Cancer Society (ACS)</b></div><div>250 Williams Street Northwest</div><div>Atlanta GA 30303</div><div><b>Phone:</b> 800-227-2345 (toll-free 24/7); 866-228-4327 (toll-free 24/7 TTY)</div><div><a href="http://www.cancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.org</a></div></li><li class="half_rhythm"><div><b>CancerCare</b></div><div>275 Seventh Avenue</div><div>22nd Floor</div><div>New York NY 10001</div><div><b>Phone:</b> 800-813-4673 (toll-free); 212-712-8400 (administrative)</div><div><b>Fax:</b> 212-712-8495</div><div><b>Email:</b> info@cancercare.org</div><div><a href="http://www.cancercare.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancercare.org</a></div></li></ul></div><div id="bap1-tpds.Molecular_Genetics"><h2 id="_bap1-tpds_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="bap1-tpds.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>BAP1 Tumor Predisposition Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK390611/table/bap1-tpds.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bap1-tpds.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_bap1-tpds.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_bap1-tpds.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_bap1-tpds.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_bap1-tpds.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_bap1-tpds.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_bap1-tpds.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_bap1-tpds.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8314" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BAP1</i></a></td><td headers="hd_b_bap1-tpds.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8314" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p21<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_bap1-tpds.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q92560" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ubiquitin carboxyl-terminal hydrolase BAP1</a></td><td headers="hd_b_bap1-tpds.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/BAP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BAP1 @ LOVD</a></td><td headers="hd_b_bap1-tpds.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BAP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BAP1</a></td><td headers="hd_b_bap1-tpds.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BAP1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BAP1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="bap1-tpds.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="bap1-tpds.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for BAP1 Tumor Predisposition Syndrome (<a href="/omim/603089,614327" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK390611/table/bap1-tpds.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bap1-tpds.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603089" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603089</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRCA1-ASSOCIATED PROTEIN 1; BAP1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614327" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614327</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TUMOR PREDISPOSITION SYNDROME; TPDS</td></tr></tbody></table></div></div><div id="bap1-tpds.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Although it has been been suggested that BAP1 functions as a tumor suppressor, this has not been completely established [<a class="bk_pop" href="#bap1-tpds.REF.kadariya.2016.2836">Kadariya et al 2016</a>]. It is a nuclear-localized deubiquitinating enzyme and acts as a chromatin-associated protein that is part of large multi-protein complexes which both positively and negatively regulate cellular proliferation [reviewed in <a class="bk_pop" href="#bap1-tpds.REF.daou.2015.28643">Daou et al 2015</a>]. It is recruited to promoter regions of genes involved in cellular proliferation to activate transcription and to promote repair at sites of DNA double strand breaks through homologous <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> [<a class="bk_pop" href="#bap1-tpds.REF.daou.2015.28643">Daou et al 2015</a>].</p><p><b>Gene structure.</b> The <i>BAP1</i> transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_004656.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004656.3</a> has 3717 base pairs and 17 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK390611/#bap1-tpds.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Reported pathogenic (cancer-predisposing) variants include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants and small deletions and duplications (see <a href="/books/NBK390611/#bap1-tpds.molgen.TA">Table A</a>, <b>HGMD</b>).</p><p>One apparent <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> has been reported in four American families of German origin [<a class="bk_pop" href="#bap1-tpds.REF.carbone.2015.e1005633">Carbone et al 2015</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The human BAP1 protein <a href="/protein/NP_004647.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004647.1</a> has 729 amino acids. Critical domains include: ubiquitin C-terminal hydrolase, BARD binding, HCF1 binding, ASXL1/2 binding, an ATM-dependent serine 592 phosphorylation site, and BRCA1 binding, as well as a nuclear localizing signal.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>BAP1</i>-TPDS is caused by a cancer-predisposing variant in one <i>BAP1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> resulting in <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> of the tumor suppressor protein BAP1. Tumors develop from certain cell types in which the second allele undergoes somatic mutation resulting in a complete absence of BAP1 tumor suppressor activity. Most atypical Spitz tumors (ASTs) analyzed by <a class="bk_pop" href="#bap1-tpds.REF.wiesner.2012.818">Wiesner et al [2012]</a> showed loss of the remaining normal <i>BAP1</i> allele by various somatic alterations and all showed loss of BAP1 protein in the nucleus.</p><div id="bap1-tpds.Cancer_and_Benign_Tumors"><h4>Cancer and Benign Tumors</h4><p>Sporadic tumors (including cholangiocarcinoma, mesothelioma, renal cell carcinoma and uveal melanoma) may occur as single tumors in the absence of any other findings of <i>BAP1</i>-TPDS and frequently harbor somatic variants in <i>BAP1</i> that are not present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> [reviewed in <a class="bk_pop" href="#bap1-tpds.REF.rai.2016.285">Rai et al 2016</a>]. In these circumstances predisposition to these tumors is not heritable.</p></div></div></div><div id="bap1-tpds.References"><h2 id="_bap1-tpds_References_">References</h2><div id="bap1-tpds.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.abdelrahman.2011.856">Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill J, Christopher B, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma and other cancers. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:856–9.</span> [<a href="/pmc/articles/PMC3825099/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3825099</span></a>] [<a href="/pubmed/21941004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21941004</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.aoude.2015.126">Aoude LG, Gartside M, Johansson P, Palmer JM, Symmons J, Martin NG, Montgomery GW, Hayward NK. Prevalence of germline BAP1, CDKN2A, and CDK4 mutations in an Australian population-based sample of cutaneous melanoma cases. <span><span class="ref-journal">Twin Res Hum Genet. </span>2015;<span class="ref-vol">18</span>:126–33.</span> [<a href="/pubmed/25787093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25787093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.aoude.2013a.278">Aoude LG, Vajdic CM, Kricker A, Armstrong B, Hayward NK. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. <span><span class="ref-journal">Pigment Cell Melanoma Res. </span>2013a;<span class="ref-vol">26</span>:278–9.</span> [<a href="/pubmed/23171164" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23171164</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.aoude.2013b.e72144">Aoude LG, Wadt K, Bojesen A, Cr&#x000fc;ger D, Borg A, Trent JM, Brown KM, Gerdes AM, J&#x000f6;nsson G, Hayward NK. A. BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. <span><span class="ref-journal">PLoS One. </span>2013b;<span class="ref-vol">8</span>:e72144.</span> [<a href="/pmc/articles/PMC3747051/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3747051</span></a>] [<a href="/pubmed/23977234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23977234</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.battaglia.2014.37">Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. <span><span class="ref-journal">Clin Med Insights Oncol. </span>2014;<span class="ref-vol">8</span>:37–47.</span> [<a href="/pmc/articles/PMC4011723/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4011723</span></a>] [<a href="/pubmed/24855403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24855403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.baumann.2015.76">Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. <span><span class="ref-journal">Carcinogenesis. </span>2015;<span class="ref-vol">36</span>:76–81.</span> [<a href="/pmc/articles/PMC4291047/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4291047</span></a>] [<a href="/pubmed/25380601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25380601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.betti.2015.51">Betti M, Casalone E, Ferrante D, Romanelli A, Grosso F, Guarrera S, Righi L, Vatrano S, Pelosi G, Libener R, Mirabelli D, Boldorini R, Casadio C, Papotti M, Matullo G, Magnani C, Dianzani I. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. <span><span class="ref-journal">Genes Chrom Cancer. </span>2015;<span class="ref-vol">54</span>:51–62.</span> [<a href="/pubmed/25231345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25231345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.carbone.2012.179">Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, Hyjek E, Tate R, Friedberg J, Weigel T, Pass HI, Yang H. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. <span><span class="ref-journal">J Transl Med. </span>2012;<span class="ref-vol">10</span>:179.</span> [<a href="/pmc/articles/PMC3493315/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3493315</span></a>] [<a href="/pubmed/22935333" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22935333</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.carbone.2015.e1005633">Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, Hoffman H, Hesdorffer M, Nasu M, Napolitano A, Powers A, Minaai M, Baumann F, Bryant-Greenwood P, Lauk O, Kirschner MB, Weder W, Opitz I, Pass HI, Gaudino G, Pastorino S, Yang H. Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. <span><span class="ref-journal">PLoS Genet. </span>2015;<span class="ref-vol">11</span>:e1005633.</span> [<a href="/pmc/articles/PMC4686043/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4686043</span></a>] [<a href="/pubmed/26683624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26683624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.cheung.2015.261">Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. <span><span class="ref-journal">Cancer Lett. </span>2015;<span class="ref-vol">369</span>:261–5.</span> [<a href="/pmc/articles/PMC4634709/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4634709</span></a>] [<a href="/pubmed/26409435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26409435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.daou.2015.28643">Daou S, Hammond-Martel I, Mashtalir N, Barbour H, Gagnon J, Iannantuono NV, Nkwe NS, Motorina A, Pak H, Yu H, Wurtele H, Milot E, Mallette FA, Carbone M. Affar el B. The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer. <span><span class="ref-journal">J Biol Chem. </span>2015;<span class="ref-vol">290</span>:28643–63.</span> [<a href="/pmc/articles/PMC4661380/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4661380</span></a>] [<a href="/pubmed/26416890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26416890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.de_la_fouchardi_re.2015b.921">de la Fouchardi&#x000e8;re A, Cabaret O, Petre J, Aydin S, Leroy A, de Potter P, Pissaloux D, Haddad V, Bressac-de Paillerets B, Janin N. Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome. <span><span class="ref-journal">Acta Neuropathol. </span>2015b;<span class="ref-vol">129</span>:921–3.</span> [<a href="/pubmed/25900292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25900292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.de_la_fouchardi_re.2015a.273">de la Fouchardi&#x000e8;re A, Cabaret O, Savin L, Combemale P, Schvartz H, Penet C, Bonadona V, Soufir N, Bressac-de Paillerets B. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. <span><span class="ref-journal">Clin Genet. </span>2015a;<span class="ref-vol">88</span>:273–7.</span> [<a href="/pubmed/25080371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25080371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.de_reyni_s.2014.1323">de Reyni&#x000e8;s A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sall&#x000e9; F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. <span><span class="ref-journal">Clin Cancer Res. </span>2014;<span class="ref-vol">20</span>:1323–34.</span> [<a href="/pubmed/24443521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24443521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.farley.2013.1061">Farley MN, Schmidt LS, Mester JL, Pe&#x000f1;a-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, Brugarolas J. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. <span><span class="ref-journal">Mol Cancer Res. </span>2013;<span class="ref-vol">11</span>:1061–71.</span> [<a href="/pmc/articles/PMC4211292/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4211292</span></a>] [<a href="/pubmed/23709298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23709298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.gupta.2015.881">Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES, Kim IK. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. <span><span class="ref-journal">JAMA Ophthalmol. </span>2015;<span class="ref-vol">133</span>:881–7.</span> [<a href="/pubmed/25974357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25974357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.haas.2014.81">Haas NB, Nathanson N. Hereditary kidney cancer syndromes. <span><span class="ref-journal">Adv Chronic Kidney Dis. </span>2014;<span class="ref-vol">21</span>:81–90.</span> [<a href="/pmc/articles/PMC3872053/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3872053</span></a>] [<a href="/pubmed/24359990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24359990</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.iscovich.2002.42">Iscovich J, Abdulrazik M, Cour C, Fischbein A, Pe'er J, Goldgar DE. Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. <span><span class="ref-journal">Int J Cancer. </span>2002;<span class="ref-vol">98</span>:42–44.</span> [<a href="/pubmed/11857383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11857383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.kadariya.2016.2836">Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. <span><span class="ref-journal">Cancer Res. </span>2016;<span class="ref-vol">76</span>:2836–44.</span> [<a href="/pmc/articles/PMC4873414/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4873414</span></a>] [<a href="/pubmed/26896281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26896281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.kalirai.2014.1373">Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. <span><span class="ref-journal">Br J Cancer. </span>2014;<span class="ref-vol">111</span>:1373–80.</span> [<a href="/pmc/articles/PMC4183849/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4183849</span></a>] [<a href="/pubmed/25058347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25058347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.kumar.2015.1089">Kumar R, Taylor M, Miao B, Ji Z, Njauw JC, J&#x000f6;nsson G, Frederick DT, Tsao H. BAP1 has a survival role in cutaneous melanoma. <span><span class="ref-journal">J Invest Dermatol. </span>2015;<span class="ref-vol">135</span>:1089–97.</span> [<a href="/pmc/articles/PMC4366338/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4366338</span></a>] [<a href="/pubmed/25521456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25521456</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.marzukaalcal_.2014.381">Marzuka-Alcal&#x000e1; A, Gabree MJ, Tsao H. Melanoma Susceptibility Genes and Risk Assessment. <span><span class="ref-journal">Methods Mol Biol. </span>2014;<span class="ref-vol">1102</span>:381–93.</span> [<a href="/pubmed/24258989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24258989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.mcdonnell.2016.75">McDonnell KJ, Gallanis GT, Heller KA, Melas M, Idos GI, Culver JO, Martin S-E, Peng DH, Gruber SB. A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer. <span><span class="ref-journal">Cancer Genet. </span>2016;<span class="ref-vol">209</span>:75–81.</span> [<a href="/pmc/articles/PMC6447287/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6447287</span></a>] [<a href="/pubmed/26774355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26774355</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.mochel.2015.901">Mochel MC, Piris A, Nose V, Hoang MP. Loss of BAP1 expression in basal cell carcinomas in patients with germline BAP1 mutations. <span><span class="ref-journal">Am J Clin Pathol. </span>2015;<span class="ref-vol">143</span>:901–4.</span> [<a href="/pubmed/25972334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25972334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.njauw.2012.e35295">Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. <span><span class="ref-journal">PLoS One. </span>2012;<span class="ref-vol">7</span>:e35295.</span> [<a href="/pmc/articles/PMC3335872/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3335872</span></a>] [<a href="/pubmed/22545102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22545102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.ohar.2016.206">Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. <span><span class="ref-journal">Cancer Res. </span>2016;<span class="ref-vol">76</span>:206–15.</span> [<a href="/pmc/articles/PMC4715907/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4715907</span></a>] [<a href="/pubmed/26719535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26719535</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.pe_allopis.2012.751">Pe&#x000f1;a-Llopis S, Vega-Rub&#x000ed;n-de-Celis S, Liao A, Leng N, Pav&#x000ed;a-Jim&#x000e9;nez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SW, Grishin N, Laurent M, Xie XJ, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J. BAP1 loss defines a new class of renal cell carcinoma. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:751–9.</span> [<a href="/pmc/articles/PMC3788680/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3788680</span></a>] [<a href="/pubmed/22683710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22683710</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.pilarski.2014.177">Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong L, McGillivray B, Asrat M-J, Carbon M, Davidorf FH, Abdel-Rahman MH. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2014;<span class="ref-vol">53</span>:177–82.</span> [<a href="/pmc/articles/PMC4041196/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4041196</span></a>] [<a href="/pubmed/24243779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24243779</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.popova.2013.974">Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d'Enghien C, Richaudeau B, Renaudin X, Sellers J, Nicolas A, Sastre-Garau X, Desjardins L, Gyapay G, Raynal V, Sinilnikova OM, Andrieu N, Mani&#x000e9; E, de Pauw A, Gesta P, Bonadona V, Maugard CM, Penet C, Avril MF, Barillot E, Cabaret O, Delattre O, Richard S, Caron O, Benfodda M, Hu HH, Soufir N, Bressac-de Paillerets B, Stoppa-Lyonnet D, Stern MH. Germline BAP1 mutations predispose to renal cell carcinomas. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:974–80.</span> [<a href="/pmc/articles/PMC3675229/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3675229</span></a>] [<a href="/pubmed/23684012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23684012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.rai.2016.285">Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. <span><span class="ref-journal">Clin Genet. </span>2016;<span class="ref-vol">89</span>:285–94.</span> [<a href="/pmc/articles/PMC4688243/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4688243</span></a>] [<a href="/pubmed/26096145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26096145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.rusch.2014.271">Rusch VW, Rimner A, Krug LM. The challenge of malignant pleural mesothelioma: new directions. <span><span class="ref-journal">J Thorac Oncol. </span>2014;<span class="ref-vol">9</span>:271–2.</span> [<a href="/pubmed/24518084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24518084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.scott.2002.188">Scott RJ, Vajdic CM, Armstrong BK, Ainsworth CJ, Meldrum CJ, Aitken JF, Kricker A. BRCA2 mutations in a population-based series of patients with ocular melanoma. <span><span class="ref-journal">Int J Cancer. </span>2002;<span class="ref-vol">102</span>:188–91.</span> [<a href="/pubmed/12385017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12385017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.singhi.2016.14">Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ, Luvison A, Fuhrer K, Bahary N, Seethala RR, Dacic S. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. <span><span class="ref-journal">Mod Pathol. </span>2016;<span class="ref-vol">29</span>:14–24.</span> [<a href="/pubmed/26493618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26493618</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.sinilnikova.1999.325">Sinilnikova OM, Egan KM, Quinn JL, Boutrand L, Lenoir GM, Stoppa-Lyonnet D, Desjardins L, Levy C, Goldgar D, Gragoudas ES. Germline brca2 sequence variants in patients with ocular melanoma. <span><span class="ref-journal">Int J Cancer. </span>1999;<span class="ref-vol">82</span>:325–8.</span> [<a href="/pubmed/10399947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10399947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.sneddon.2015.103">Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJN, Moses EK, Melton PE, de Klerk N, Musk AW, Robinson BWS, Creaney J. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. <span><span class="ref-journal">Gene. </span>2015;<span class="ref-vol">563</span>:103–5.</span> [<a href="/pubmed/25796603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25796603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.testa.2011.1022">Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:1022–5.</span> [<a href="/pmc/articles/PMC3184199/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3184199</span></a>] [<a href="/pubmed/21874000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21874000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.turunen.2016.1112">Turunen JA, Markkinen S, Wilska R, Saarinen S, Raivio V, T&#x000e4;ll M, Lehesjoki AE, Kivel&#x000e4; TT. BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma. <span><span class="ref-journal">Ophthalmology. </span>2016;<span class="ref-vol">123</span>:1112–7.</span> [<a href="/pubmed/26876698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26876698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.wadt.2012.815">Wadt K, Choi J, Chung JY, Kiilgaard J, Heegaard S, Drzewiecki KT, Trent JM, Hewitt SM, Hayward NK, Gerdes AM, Brown KM. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. <span><span class="ref-journal">Pigment Cell Melanoma Res. </span>2012;<span class="ref-vol">25</span>:815–8.</span> [<a href="/pubmed/22889334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22889334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.wadt.2015.267">Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, Andersen MT, Kiilgaard JF, Heegaard S, Sunde L, Federspiel B, Madore J, Thompson JF, McCarthy SW, Goodwin A, Tsao H, J&#x000f6;nsson G, Busam K, Gupta R, Trent JM, Gerdes AM, Brown KM, Scolyer RA, Hayward NK. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. <span><span class="ref-journal">Clin Genet. </span>2015;<span class="ref-vol">88</span>:267–72.</span> [<a href="/pubmed/25225168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25225168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.wiesner.2012.818">Wiesner T, Murali R, Fried I, Cerroni L, Busam K, Kutzner H, Bastian BC. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. <span><span class="ref-journal">Am J Surg Pathol. </span>2012;<span class="ref-vol">36</span>:818–30.</span> [<a href="/pmc/articles/PMC3354018/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3354018</span></a>] [<a href="/pubmed/22367297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22367297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.wiesner.2011.1018">Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, R&#x000fc;tten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP1 predispose to melanocytic tumors. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:1018–21.</span> [<a href="/pmc/articles/PMC3328403/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3328403</span></a>] [<a href="/pubmed/21874003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21874003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bap1-tpds.REF.xu.2014.4388">Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ, Testa JR. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. <span><span class="ref-journal">Cancer Res. </span>2014;<span class="ref-vol">74</span>:4388–97.</span> [<a href="/pmc/articles/PMC4165574/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4165574</span></a>] [<a href="/pubmed/24928783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24928783</span></a>]</div></li></ul></div></div><div id="bap1-tpds.Chapter_Notes"><h2 id="_bap1-tpds_Chapter_Notes_">Chapter Notes</h2><div id="bap1-tpds.Author_Notes"><h3>Author Notes</h3><p>Author&#x02019;s <a href="http://eye.osu.edu/research/articles/melanoma/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">website</a></p><p>Our group&#x02019;s research is focused on identifying and characterizing hereditary causes of uveal melanoma. We were one of three groups co-reporting on the identification of the <i>BAP1</i> tumor predisposition syndrome. We offer research analysis of <i>BAP1</i> in families with histories suggestive of <i>BAP1</i>-TPDS and are performing <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> and other analyses on high-risk UM families without identifiable genetic causes. To discuss enrolling a patient please contact <a href="mailto:dev@null" data-email="ude.cmuso@iksralip.trebor" class="oemail">ude.cmuso@iksralip.trebor</a>.</p></div><div id="bap1-tpds.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>13 October 2016 (bp) Review posted live</div></li><li class="half_rhythm"><div>3 May 2016 (rp) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK390611</span><span class="label">PMID: <a href="/pubmed/27748099" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">27748099</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/li-ar/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bcl11a-id/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK390611&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK390611/?report=reader">PubReader</a></li><li><a href="/books/NBK390611/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK390611" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK390611" style="display:none" title="Cite this Page"><div class="bk_tt">Pilarski R, Rai K, Cebulla C, et al. BAP1 Tumor Predisposition Syndrome. 2016 Oct 13. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK390611/pdf/Bookshelf_NBK390611.pdf">PDF version of this page</a> (224K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#bap1-tpds.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#bap1-tpds.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#bap1-tpds.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#bap1-tpds.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#bap1-tpds.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#bap1-tpds.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#bap1-tpds.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#bap1-tpds.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#bap1-tpds.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#bap1-tpds.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#bap1-tpds.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8314[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BAP1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4330566" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4330566" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4330566" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4330566" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29215836" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rhabdoid Tumor Predisposition Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rhabdoid Tumor Predisposition Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nemes K, Bens S, Bourdeaut F, Hasselblatt M, Kool M, Johann P, Kordes U, Schneppenheim R, Siebert R, Frühwald MC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31382694" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.</a><span class="source">[Cancers (Basel). 2019]</span><div class="brieflinkpop offscreen_noflow">Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chau C, van Doorn R, van Poppelen NM, van der Stoep N, Mensenkamp AR, Sijmons RH, van Paassen BW, van den Ouweland AMW, Naus NC, van der Hout AH, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cancers (Basel). 2019 Aug 4; 11(8). Epub 2019 Aug 4.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30477459" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.</a><span class="source">[BMC Cancer. 2018]</span><div class="brieflinkpop offscreen_noflow">Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ewens KG, Lalonde E, Richards-Yutz J, Shields CL, Ganguly A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Cancer. 2018 Nov 26; 18(1):1172. Epub 2018 Nov 26.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301488" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schneider K, Zelley K, Nichols KE, Garber J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30578689" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Basal cell carcinomas developing independently from BAP1-tumor predisposition syndrome in a patient with bilateral uveal melanoma: Diagnostic challenges to identify patients with BAP1-TPDS.</a><span class="source">[Genes Chromosomes Cancer. 2019]</span><div class="brieflinkpop offscreen_noflow">Basal cell carcinomas developing independently from BAP1-tumor predisposition syndrome in a patient with bilateral uveal melanoma: Diagnostic challenges to identify patients with BAP1-TPDS.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Melzer C, Sharma A, Peters S, Aretz S, Biswas A, Holz FG, Loeffler KU, Herwig-Carl MC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Genes Chromosomes Cancer. 2019 Jun; 58(6):357-364. Epub 2019 Jan 23.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=27748099" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=27748099" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042925dde089116999ec96">BAP1 Tumor Predisposition Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">BAP1 Tumor Predisposition Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:29:41-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BE21AE04180B10000000007DA02F9&amp;ncbi_session=CE8BE21AE0429251_2010SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK390611%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK390611&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK390611/&amp;ncbi_pagename=BAP1 Tumor Predisposition Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BE21AE0429251_2010SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>